Key Highlights

  • Aytu BioPharma (NASDAQ:AYTU) agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings through a cash tender offer at USD 2.70 per share, with closing expected by the end of the calendar year.
  • Net Revenue for the quarter ended September 30, 2026 rose 6.9% to USD 14.8 million, led by USD 4.9 million from EXXUA, while the ADHD portfolio fell to USD 7.7 million from USD 13.2 million.
  • The company reported a net loss of USD 3.9 million against Net Income of USD 2.0 million a year earlier, when a USD 3.8 million gain on Warrant liabilities lifted results.
  • Cash and cash equivalents were USD 25.5 million at September 30, 2026, down from USD 26.3 million at June 30, 2026, and Operating Activities used USD 0.3 million in the quarter.

Rosemont Tender Offer Frames the Quarter

Aytu BioPharma (NASDAQ:AYTU) filed its Quarterly Report on November 16, 2026, the same day it signed a Merger agreement with Rosemont Pharmaceuticals Holdings. Rosemont will start a cash tender offer for all outstanding common shares at USD 2.70 each, followed by a merger that leaves Aytu as a wholly owned subsidiary. Completion depends on customary conditions, including the tender of a majority of shares, and the parties expect closing by the end of the calendar year. If the agreement ends under specified circumstances, Aytu may owe Rosemont a termination fee of USD 2.4 million. With 10,868,208 shares outstanding at November 9, 2026, USD 2.70 a share implies roughly USD 29.3 million of Equity value (calculated, basic shares only).

EXXUA Launch Pulls Revenue Away From ADHD Products

Aytu is a pharmaceutical company focused on central nervous system conditions, selling EXXUA for major depressive disorder, an ADHD portfolio and a pediatric portfolio. Net revenue for the three months ended September 30, 2026 was USD 14.8 million versus USD 13.9 million a year earlier. EXXUA contributed USD 4.9 million, compared with none in the prior-year period, under a commercialization agreement with Fabre-Kramer signed in June 2025. ADHD revenue fell by USD 5.4 million as sales resources shifted to EXXUA and a generic version of one ADHD product launched. Pediatric revenue rose to USD 2.2 million from USD 0.7 million on better payer mix and lower returns. Gross Margin eased to 64% from 66% on higher EXXUA royalties.

Launch Spending and Deal Costs Turn Income Into a Loss

Operating expenses climbed to USD 13.4 million from USD 10.7 million. Selling and Marketing rose 24.4% to USD 6.6 million on EXXUA launch costs, and general and administrative expense rose 21.5% to USD 6.0 million on litigation with Granules over generic Adzenys and deal-related fees. The loss from operations was USD 3.9 million versus USD 1.5 million. Last year's profit relied on a USD 3.8 million warrant gain, against USD 0.3 million this time. Management believes cash, Operating Cash Flow and revolver availability cover at least 12 months. USD 100.0 million remains on a shelf registration, but the merger agreement restricts new equity or Debt without Rosemont's consent.

Where Things Stand

Yes, subject to conditions. Aytu BioPharma (NASDAQ:AYTU) reported a USD 3.9 million net loss, EXXUA sales of USD 4.9 million and a shrinking ADHD book, and on the same day agreed to a Rosemont cash tender offer at USD 2.70 a share. The filing sets out terms, not a valuation, so the loss and the price should be read separately. The offer still needs a majority of shares tendered and other customary conditions, and a USD 2.4 million termination fee applies in specified cases. Next markers are the tender launch, any extension, the Granules Patent case and the targeted year-end close.